Availability for Non-Exclusive or Partially Exclusive Licensing of a U.S. Patent Application, 39667-39668 [2010-16891]

Download as PDF Federal Register / Vol. 75, No. 132 / Monday, July 12, 2010 / Notices is also available on the CPSC Web site at http://www.cpsc.gov. DEPARTMENT OF DEFENSE Dated: July 6, 2010. Todd A. Stevenson, Secretary, Consumer Product Safety Commission. Department of the Army Availability for Non-Exclusive or Partially Exclusive Licensing of a U.S. Patent Application [FR Doc. 2010–16918 Filed 7–9–10; 8:45 am] ACTION: DEPARTMENT OF DEFENSE Department of the Army Availability for Non-Exclusive or Partially Exclusive Licensing of a U.S. Patent Application Department of the Army, DoD. Notice. AGENCY: ACTION: erowe on DSK5CLS3C1PROD with NOTICES SUMMARY: Announcement is made of the availability for licensing of the invention set forth in U.S. Patent 7,632,659, which issued on December 15, 2009, entitled ‘‘Use of Shigella Invaplex to Transport Functional Proteins and Transcriptionally Active Nucleic Acids Across Mammalian Cell Membranes In Vitro and In Vivo,’’ and U.S. Patent Application Serial No. 12/ 563,794, entitled ‘‘Use of Shigella Invaplex to Transport Functional Proteins and Transcriptionally Active Nucleic Acids Across Mammalian Cell Membranes In Vitro and In Vivo,’’ filed September 21, 2009. U.S. Patent Application Serial No. 12/563,794 is a continuation application of U.S. Patent 7,632,659. Foreign rights are also available for licensing (PCT/US2004/ 039100). The United States Government, as represented by the Secretary of the Army, has rights to this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034. SUPPLEMENTARY INFORMATION: The inventions relate to the use of Invaplex to transport materials, including functional proteins and biologically active nucleic acids, across eukaryotic cell membranes. Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. 2010–16889 Filed 7–9–10; 8:45 am] BILLING CODE 3710–08–P VerDate Mar<15>2010 14:19 Jul 09, 2010 Department of the Army, DoD. Notice. AGENCY: BILLING CODE 6355–01–P Jkt 220001 SUMMARY: Announcement is made of the availability for licensing of the invention set forth in U.S. Patent Application Serial No. 11/727,486, entitled ‘‘Artificial Invaplex,’’ filed March 27, 2007. Foreign rights are also available for licensing (PCT/US2007/ 007482). The United States Government, as represented by the Secretary of the Army, has rights to this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034. SUPPLEMENTARY INFORMATION: The invention relates to an artificial invasin complex hat can facilitate the transport of biomolecules, therapeutics and antibiotics across cell membranes in a manner similar to native Shigella Invaplex. Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. 2010–16897 Filed 7–9–10; 8:45 am] BILLING CODE 3710–08–P DEPARTMENT OF DEFENSE Department of the Army Availability for Non-Exclusive or Partially Exclusive Licensing of a U.S. Patent Application Department of the Army, DoD. Notice. AGENCY: ACTION: Announcement is made of the availability for licensing of the invention set forth in U.S. Patent Application Serial No. 12/149,076, entitled ‘‘Combinations of Gene Deletions for Live Attenuated Shigella Vaccine Strains,’’ filed April 25, 2008. Foreign rights are also available for licensing (PCT/US2008/005342). The United States Government, as SUMMARY: PO 00000 Frm 00016 Fmt 4703 Sfmt 4703 39667 represented by the Secretary of the Army, has rights to this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034. SUPPLEMENTARY INFORMATION: The invention relates generally to Shigella vaccine, strains, their use in vaccines, and the methods for treatment of dysentery. Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. 2010–16894 Filed 7–9–10; 8:45 am] BILLING CODE 3710–08–P DEPARTMENT OF DEFENSE Department of the Army Availability for Non-Exclusive or Partially Exclusive Licensing of a U.S. Patent Application Department of the Army, DoD. Notice. AGENCY: ACTION: SUMMARY: Announcement is made of the availability for licensing of the invention set forth in U.S. Patent Application Serial No. 11/132,199, entitled ‘‘Construction of Live Attenuated Shigella Vaccine Strains that Express CFA/I Antigens (CFAB and CFAE) and the B Subunit of Heat-Labile Enterotoxin (LTB) From Enterotoxigenic E. Coli,’’ filed May 19, 2005. The United States Government, as represented by the Secretary of the Army, has rights to this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034. SUPPLEMENTARY INFORMATION: The invention relates to materials and methodologies for preparing multivalent vaccines, recombinant DNA expression E:\FR\FM\12JYN1.SGM 12JYN1 39668 Federal Register / Vol. 75, No. 132 / Monday, July 12, 2010 / Notices products and more particularly to vector constructs which effectively express the cfaB, cfaE and LTB proteins in Shigella spp. without affecting the ability of the Shigella strain to invade cells of the colonic epithelium following oral administration to humans. Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. 2010–16891 Filed 7–9–10; 8:45 am] BILLING CODE 3710–08–P DEPARTMENT OF DEFENSE Department of the Army, Corps of Engineers Notice of Availability of Final Environmental Impact Statement for the Proposed Rio del Oro Specific Plan Project, in Sacramento County, CA, Corps Permit Application number SPK–1999–00590 erowe on DSK5CLS3C1PROD with NOTICES AGENCY: Department of the Army, U.S. Army Corps of Engineers, DOD. ACTION: Notice of availability. SUMMARY: Pursuant to the National Environmental Policy Act (NEPA), the U.S. Army Corps of Engineers (USACE), Sacramento District has prepared a Final Environmental Impact Statement (FEIS) for the Rio del Oro Specific Plan Project, a proposed master-planned, mixed use development within southeastern Sacramento County. On December 8, 2006, USACE published a notice in the Federal Register (71 FR 71142), informing the public of the availability of the Draft Environmental Impact Statement (DEIS) that analyzes the potential effects of implementing each of five alternative scenarios for a mixed-use development in the approximately 3,828-acre Rio del Oro Specific Plan Area. In response to new information and comments received on the DEIS, on May 7, 2008, USACE published a notice in the Federal Register (73 FR 25687) which provides new information and additional analyses related to utilities and service systems (specifically water supply) and provides additional analyses of each of the five alternative scenarios analyzed in the 2006 DEIS. The FEIS has been prepared to respond to comments received from agencies, organizations, and members of the public on the 2006 DEIS and 2008 SDEIS, and to present corrections, revisions, and other clarifications and amplifications of the 2006 DEIS and 2008 SDEIS, including minor project modifications made in response to these comments and as a result of the applicants’ ongoing planning efforts. VerDate Mar<15>2010 14:19 Jul 09, 2010 Jkt 220001 The FEIS has been prepared as joint documents with the City of Rancho Cordova (City). The City is the local agency responsible for preparing an Environmental Impact Report in compliance with the California Environmental Quality Act (CEQA). The USACE is the lead Federal agency responsible for the FEIS and information contained in the DEIS, SDEIS and FEIS serves as the basis for a decision regarding issuance of an individual permit under section 404 of the Clean Water Act. It also provides information for Federal, State and local agencies having jurisdictional responsibility for affected resources. All incoming comments on the FEIS will be considered by USACE and responses will be provided for substantive issues raised which have not been addressed in the DEIS, SDEIS or FEIS. DATES: All written comments must be postmarked on or before August 9, 2010. ADDRESSES: Comments may be submitted in writing to: Lisa M. Gibson, U.S. Army Corps of Engineers, Sacramento District, Regulatory Division; 1325 J Street, Room 1480, Sacramento, CA 95814–2922, or via email to Lisa.M.Gibson2@usace.army.mil. FOR FURTHER INFORMATION CONTACT: Lisa M. Gibson, (916) 557–5288, or via e-mail at Lisa.M.Gibson2@usace.army.mil. SUPPLEMENTARY INFORMATION: Elliott Homes, Inc., and GenCorp, the project applicants, are requesting a Section 404 individual permit from USACE for the placement of fill material into 27.903 acres of waters of the United States for the construction of the Rio del Oro Specific Plan project, which involves the construction of a mixed use development that supports a combination of employment generating uses, retail and supporting services, recreational uses, and a broad range of residential uses and associated infrastructure and roads on an approximately 3,828-acre site in eastern Sacramento County, south of U.S. Highway 50. The FEIS is available for review at the following locations: (1) An electronic version of the FEIS may be downloaded and reviewed at the USACE, Sacramento District Web site: http://www.spk.usace.army.mil/ organizations/cespk-co/regulatory/EISs/ EIS-index.html: (2) A hardcopy of the FEIS will be available for review by appointment only at USACE, Sacramento District, 1325 J Street, Sacramento, CA 95814– 2922. To schedule an appointment please contact Lisa M. Gibson at (916) 557–5288. PO 00000 Frm 00017 Fmt 4703 Sfmt 9990 (3) A hardcopy of the FEIS will be available for review at the City of Rancho Cordova City Hall, Planning Department, 2729 Prospect Park Drive, Rancho Cordova, CA 95670. Dated: June 24, 2010. Thomas C. Chapman, Colonel, U.S. Army, District Engineer. [FR Doc. 2010–16899 Filed 7–9–10; 8:45 am] BILLING CODE 3720–58–P DEPARTMENT OF DEFENSE Department of the Army Intent To Grant a Field of Use Exclusive License of a U.S. Government-Owned Patent Application AGENCY: ACTION: Department of the Army, DoD. Notice. SUMMARY: In accordance with 35 U.S.C. 209(e), and 37 CFR 404.7(a)(1)(i), announcement is made of the intent to grant a field of use exclusive, revocable license for the field of shigella vaccine development to U.S. Patent Application No. 11/727,486 entitled ‘‘Artificial Invaplex,’’ filed March 27, 2007, and related foreign patent applications (PCT/US2007,007482) to Sanofi Pasteur S.A., with its principal place of business at 2 Avenue du Pont Pasteur, 69007 Lyon, France. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, Attn: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012. FOR FURTHER INFORMATION CONTACT: For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664. For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808, both at telefax (301) 619–5034. Anyone wishing to object to the grant of this license can file written objections along with supporting evidence, if any, within 15 days from the date of this publication. Written objections are to be filed with the Command Judge Advocate (see ADDRESSES). SUPPLEMENTARY INFORMATION: Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. 2010–16887 Filed 7–9–10; 8:45 am] BILLING CODE 3710–08–P E:\FR\FM\12JYN1.SGM 12JYN1

Agencies

[Federal Register Volume 75, Number 132 (Monday, July 12, 2010)]
[Notices]
[Pages 39667-39668]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-16891]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability for Non-Exclusive or Partially Exclusive Licensing 
of a U.S. Patent Application

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Announcement is made of the availability for licensing of the 
invention set forth in U.S. Patent Application Serial No. 11/132,199, 
entitled ``Construction of Live Attenuated Shigella Vaccine Strains 
that Express CFA/I Antigens (CFAB and CFAE) and the B Subunit of Heat-
Labile Enterotoxin (LTB) From Enterotoxigenic E. Coli,'' filed May 19, 
2005. The United States Government, as represented by the Secretary of 
the Army, has rights to this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research and Technology Applications (ORTA), (301) 619-
6664, both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: The invention relates to materials and 
methodologies for preparing multivalent vaccines, recombinant DNA 
expression

[[Page 39668]]

products and more particularly to vector constructs which effectively 
express the cfaB, cfaE and LTB proteins in Shigella spp. without 
affecting the ability of the Shigella strain to invade cells of the 
colonic epithelium following oral administration to humans.

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2010-16891 Filed 7-9-10; 8:45 am]
BILLING CODE 3710-08-P